Zhaoying Fu
Research Subjects
Research Interests
Zhaoying Fu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Jim Xiang
Research Unit, Saskatchewan Cancer Agency, 20 Campus Drive, Saskatoon, Saskatchewan S7N 4H4, Canada
2 shared publications Ai-Hong Wang
Zhao-Ying Fu, Institute of Molecular Biology and Immunology, Yan'an University, Yan'an 716000, Shaanxi Province, China
1 shared publication- Juan Du
Basic Medical Research and Experiment Center, School of Medicine, Yan'an University
1 shared publication Jun Zheng
Yan’an Medical College
1 shared publicationLifang Zhao
Affiliated Hospital, Yan'an University, Yan'an, Shaanxi Province 716000, China
1 shared publicationQiuxia Pang
Yan’an Medical College
1 shared publication
Latest Publications
- Open Access
- 21 April 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (16) , 15840-15851
Replication Features of SARS-CoV-2 and Advantages of Targeting S Protein with Aptamers to Block Viral Entry
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus of the coronaviridae family. The virus enters the cell through binding to the corresponding receptor angiotensin-converting enzyme 2 (ACE2) on host cell membrane with the spike protein (S protein) on its envelope; thus, we can design inhibitors that bind the S protein to block the entry of the virus into cells. Aptamers are single stranded DNA or RNA molecules that can form specific three-dimensional structures and bind their target molecules with high affinity and specificity and thus are promising candidates for S protein inhibitors. This paper reviews the replication cycle and cell entry mechanisms of SARS-CoV-2 as well as the preparation principle and characteristics of aptamers, features a discussion of the advantages of using aptamers to target the S protein to prevent SARS-CoV-2 from infecting cells, and finally summarizes the research progress in S protein-blocking aptamers.
- 21 April 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (16) , 15840-15851
Open AccessReplication Features of SARS-CoV-2 and Advantages of Targeting S Protein with Aptamers to Block Viral Entry
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus of the coronaviridae family. The virus enters the cell through binding to the corresponding receptor angiotensin-converting enzyme 2 (ACE2) on host cell membrane with the spike protein (S protein) on its envelope; thus, we can design inhibitors that bind the S protein to block the entry of the virus into cells. Aptamers are single stranded DNA or RNA molecules that can form specific three-dimensional structures and bind their target molecules with high affinity and specificity and thus are promising candidates for S protein inhibitors. This paper reviews the replication cycle and cell entry mechanisms of SARS-CoV-2 as well as the preparation principle and characteristics of aptamers, features a discussion of the advantages of using aptamers to target the S protein to prevent SARS-CoV-2 from infecting cells, and finally summarizes the research progress in S protein-blocking aptamers.
- Top Cited PapersOpen Access
- 30 November 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (23) , 9123
Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy
Using nanoparticles to carry and delivery anticancer drugs holds much promise in cancer therapy, but nanoparticles per se are lacking specificity. Active targeting, that is, using specific ligands to functionalize nanoparticles, is attracting much attention in recent years. Aptamers, with their several favorable features like high specificity and affinity, small size, very low immunogenicity, relatively low cost for production, and easiness to store, are one of the best candidates for the specific ligands of nanoparticle functionalization. This review discusses the benefits and challenges of using aptamers to functionalize nanoparticles for active targeting and especially presents nearly all of the published works that address the topic of using aptamers to functionalize nanoparticles for targeted drug delivery and cancer therapy.
- 30 November 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (23) , 9123
Top Cited PapersOpen AccessAptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy
Using nanoparticles to carry and delivery anticancer drugs holds much promise in cancer therapy, but nanoparticles per se are lacking specificity. Active targeting, that is, using specific ligands to functionalize nanoparticles, is attracting much attention in recent years. Aptamers, with their several favorable features like high specificity and affinity, small size, very low immunogenicity, relatively low cost for production, and easiness to store, are one of the best candidates for the specific ligands of nanoparticle functionalization. This review discusses the benefits and challenges of using aptamers to functionalize nanoparticles for active targeting and especially presents nearly all of the published works that address the topic of using aptamers to functionalize nanoparticles for targeted drug delivery and cancer therapy.
- Open Access
- 17 April 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (8) , 2793
Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy
The arrival of the monoclonal antibody (mAb) technology in the 1970s brought with it the hope of conquering cancers to the medical community. However, mAbs, on the whole, did not achieve the expected wonder in cancer therapy although they do have demonstrated successfulness in the treatment of a few types of cancers. In 1990, another technology of making biomolecules capable of specific binding appeared. This technique, systematic evolution of ligands by exponential enrichment (SELEX), can make aptamers, single-stranded DNAs or RNAs that bind targets with high specificity and affinity. Aptamers have some advantages over mAbs in therapeutic uses particularly because they have little or no immunogenicity, which means the feasibility of repeated use and fewer side effects. In this review, the general properties of the aptamer, the advantages and limitations of aptamers, the principle and procedure of aptamer production with SELEX, particularly the undergoing studies in aptamers for cancer therapy, and selected anticancer aptamers that have entered clinical trials or are under active investigations are summarized.
- 17 April 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (8) , 2793
Open AccessAptamers, the Nucleic Acid Antibodies, in Cancer Therapy
The arrival of the monoclonal antibody (mAb) technology in the 1970s brought with it the hope of conquering cancers to the medical community. However, mAbs, on the whole, did not achieve the expected wonder in cancer therapy although they do have demonstrated successfulness in the treatment of a few types of cancers. In 1990, another technology of making biomolecules capable of specific binding appeared. This technique, systematic evolution of ligands by exponential enrichment (SELEX), can make aptamers, single-stranded DNAs or RNAs that bind targets with high specificity and affinity. Aptamers have some advantages over mAbs in therapeutic uses particularly because they have little or no immunogenicity, which means the feasibility of repeated use and fewer side effects. In this review, the general properties of the aptamer, the advantages and limitations of aptamers, the principle and procedure of aptamer production with SELEX, particularly the undergoing studies in aptamers for cancer therapy, and selected anticancer aptamers that have entered clinical trials or are under active investigations are summarized.
- Open Access
- 7 May 2018
- Published by Wiley in Journal of Immunology Research
- Vol. 2018, 1-12
Roles of Host Immunity in Viral Myocarditis and Dilated Cardiomyopathy
The pathogenesis of viral myocarditis includes both the direct damage mediated by viral infection and the indirect lesion resulted from host immune responses. Myocarditis can progress into dilated cardiomyopathy that is also associated with immunopathogenesis. T cell-mediated autoimmunity, antibody-mediated autoimmunity (autoantibodies), and innate immunity, working together, contribute to the development of myocarditis and dilated cardiomyopathy.
- 7 May 2018
- Published by Wiley in Journal of Immunology Research
- Vol. 2018, 1-12
Open AccessRoles of Host Immunity in Viral Myocarditis and Dilated Cardiomyopathy
The pathogenesis of viral myocarditis includes both the direct damage mediated by viral infection and the indirect lesion resulted from host immune responses. Myocarditis can progress into dilated cardiomyopathy that is also associated with immunopathogenesis. T cell-mediated autoimmunity, antibody-mediated autoimmunity (autoantibodies), and innate immunity, working together, contribute to the development of myocarditis and dilated cardiomyopathy.
- 1 January 2018
- Published by SAGE Publications in Pharmacognosy Magazine
- Vol. 14 (56) , 411-417
Full extract of Euphorbia esula reversed chemoresistance, inhibited cell migration/invasion, and induced apoptosis of multidrug-resistant SGC7901/VCR cells
Background: The plant Euphorbia esula has been used by ancient Chinese people to treat cancer and other ailments and is used by present doctors or folks as an assistant treatment for some kind of cancers, but the mode of action is unclear. Objective: To investigate the influence of E. esula full extract on chemoresistance, cell migration/invasion, and apoptosis of multidrug-resistant human stomach cancer cells. Materials and Methods: After treating multidrug-resistant human stomach cancer SGC7901/VCR cells with E. esula extract at varying concentrations, the inhibition of cell proliferation was detected using thiazolyl blue. Sensitivity to the chemotherapeutic drugs, adriamycin and paclitaxel, was evaluated using half maximal inhibitory concentration. Cell cycle progression was analyzed by flow cytometry. The inhibitions of cell migration and invasion were examined by Transwell method. The induction of apoptosis and the apoptotic rate were studied by electron microscopy and flow cytometry, respectively. Activation of caspase 3 enzyme was inspected by ultraviolet spectrophotometry. Results: E. esula extract could increase the sensitivity of SGC7901/VCR cells to the chemotherapeutic drugs, adriamycin and paclitaxel. The proliferation, migration, and invasion of SGC7901/VCR cells were significantly inhibited by E. esula extract (P < 0.01 compared with negative control), which showed time- and dose-dependent manners (P < 0.05 and P < 0.01, respectively). Cell cycle was arrest at the S phase. E. esula extract also induced apoptosis in SGC7901/VCR cells, and the apoptotic rate was increased significantly with drug concentration and with treatment time (P < 0.01 compared with negative control, P < 0.05 between concentrations and time points). E. esula extract upregulated enzymatic activity of caspase 3. Conclusion: E. esula extract could reverse SGC7901/VCR cell's resistance to chemotherapeutic drugs and could inhibit cell proliferation, migration, and invasion, interfere with cell cycle progression, and induce apoptosis in SGC7901/VCR cells. Abbreviations used: E. esula: Euphorbia Esula; FCS: fetal calf serum; IC50: half maximal inhibitory concentration; OD: optical density.
- 1 January 2018
- Published by SAGE Publications in Pharmacognosy Magazine
- Vol. 14 (56) , 411-417
Full extract of Euphorbia esula reversed chemoresistance, inhibited cell migration/invasion, and induced apoptosis of multidrug-resistant SGC7901/VCR cells
Background: The plant Euphorbia esula has been used by ancient Chinese people to treat cancer and other ailments and is used by present doctors or folks as an assistant treatment for some kind of cancers, but the mode of action is unclear. Objective: To investigate the influence of E. esula full extract on chemoresistance, cell migration/invasion, and apoptosis of multidrug-resistant human stomach cancer cells. Materials and Methods: After treating multidrug-resistant human stomach cancer SGC7901/VCR cells with E. esula extract at varying concentrations, the inhibition of cell proliferation was detected using thiazolyl blue. Sensitivity to the chemotherapeutic drugs, adriamycin and paclitaxel, was evaluated using half maximal inhibitory concentration. Cell cycle progression was analyzed by flow cytometry. The inhibitions of cell migration and invasion were examined by Transwell method. The induction of apoptosis and the apoptotic rate were studied by electron microscopy and flow cytometry, respectively. Activation of caspase 3 enzyme was inspected by ultraviolet spectrophotometry. Results: E. esula extract could increase the sensitivity of SGC7901/VCR cells to the chemotherapeutic drugs, adriamycin and paclitaxel. The proliferation, migration, and invasion of SGC7901/VCR cells were significantly inhibited by E. esula extract (P < 0.01 compared with negative control), which showed time- and dose-dependent manners (P < 0.05 and P < 0.01, respectively). Cell cycle was arrest at the S phase. E. esula extract also induced apoptosis in SGC7901/VCR cells, and the apoptotic rate was increased significantly with drug concentration and with treatment time (P < 0.01 compared with negative control, P < 0.05 between concentrations and time points). E. esula extract upregulated enzymatic activity of caspase 3. Conclusion: E. esula extract could reverse SGC7901/VCR cell's resistance to chemotherapeutic drugs and could inhibit cell proliferation, migration, and invasion, interfere with cell cycle progression, and induce apoptosis in SGC7901/VCR cells. Abbreviations used: E. esula: Euphorbia Esula; FCS: fetal calf serum; IC50: half maximal inhibitory concentration; OD: optical density.
- Open Access
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 22 (13) , 3564-72
Apoptosis of human gastric carcinoma cells induced byEuphorbia esulalatex
AIM: To investigate the effect of Euphorbia esula (E. esula) extract in inhibiting proliferation and inducing apoptosis in SGC-7901 cells. METHODS: E. esula extract at different concentrations was used to inhibit proliferation and induce apoptosis of human gastric carcinoma SGC-7901 cells. Inhibition of proliferation was detected with thiazolyl blue assay, and apoptosis was detected with fluorescence microscopy, transmission electron microscopy, and flow cytometry. The mechanisms were studied by measurement of caspase-3 and caspase-8 activities and Bax and Bcl2 mRNA expression. RESULTS: The thiazolyl blue assay showed that SGC-7901 cell viability and proliferation were inhibited significantly by E. esula extract in a time- and concentration-dependent manner. Fluorescence microscopy revealed that the cell nuclei showed the characteristic changes of apoptosis, such as uneven staining and chromatin marginalization. Some key features of apoptosis were also observed under transmission electron microscopy, which included cellular shrinkage and the foaming or bubbling phenomenon. When the cells were analyzed by flow cytometry, a sub-G1 peak could be seen clearly. Spectrophotometric assay of caspase-3 and caspase-8 activities in the treated cells showed an approximately two-fold increase. Reverse transcription polymerase chain reaction showed that Bax mRNA expression was upregulated, while Bcl2 mRNA expression was downregulated. CONCLUSION: E. esula extract inhibited proliferation and induced apoptosis in SGC-7901 cells, in a caspase-dependent manner, involving upregulation of Bax and downregulation of Bcl2.
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 22 (13) , 3564-72
Open AccessApoptosis of human gastric carcinoma cells induced byEuphorbia esulalatex
AIM: To investigate the effect of Euphorbia esula (E. esula) extract in inhibiting proliferation and inducing apoptosis in SGC-7901 cells. METHODS: E. esula extract at different concentrations was used to inhibit proliferation and induce apoptosis of human gastric carcinoma SGC-7901 cells. Inhibition of proliferation was detected with thiazolyl blue assay, and apoptosis was detected with fluorescence microscopy, transmission electron microscopy, and flow cytometry. The mechanisms were studied by measurement of caspase-3 and caspase-8 activities and Bax and Bcl2 mRNA expression. RESULTS: The thiazolyl blue assay showed that SGC-7901 cell viability and proliferation were inhibited significantly by E. esula extract in a time- and concentration-dependent manner. Fluorescence microscopy revealed that the cell nuclei showed the characteristic changes of apoptosis, such as uneven staining and chromatin marginalization. Some key features of apoptosis were also observed under transmission electron microscopy, which included cellular shrinkage and the foaming or bubbling phenomenon. When the cells were analyzed by flow cytometry, a sub-G1 peak could be seen clearly. Spectrophotometric assay of caspase-3 and caspase-8 activities in the treated cells showed an approximately two-fold increase. Reverse transcription polymerase chain reaction showed that Bax mRNA expression was upregulated, while Bcl2 mRNA expression was downregulated. CONCLUSION: E. esula extract inhibited proliferation and induced apoptosis in SGC-7901 cells, in a caspase-dependent manner, involving upregulation of Bax and downregulation of Bcl2.